Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Volition logo — Revolutionizing early disease diagnosis for a brighter tomor...

Volition

Revolutionizing early disease diagnosis for a brighter tomorrow

Founded 2010 United States Henderson, United States 86 employees IPO Total: $69.10M

General Information

Company Name Volition
Founded Year 2010
Location United States Henderson, United States
Employees 86
Funding Stage IPO
Business Model B2B, B2C, B2D
Revenue Model Product Sales, Licensing, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Volition. To contact Volition, visit volition.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Volition compare?

A PDF of Volition and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Volition soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Volition

Volition, established in 2010, is on a mission to transform the landscape of disease diagnosis through its cutting-edge epigenetic technologies. Headquartered in the United States and listed on NYSE AMERICAN under VolitionRX Limited (VNRX), this innovative company seeks to change how diseases such as cancer and sepsis are diagnosed and monitored.

With a focus on early detection via routine blood tests, Volition uses patented technologies to identify biomarkers like nucleosomes and transcription factors. Their flagship Nu.Q® technology is structured around four main pillars: Nu.Q® Vet, Nu.Q® NETs, Nu.Q® Discover, and Nu.Q® Cancer. Additionally, their Capture-PCR™ offers a pioneering liquid biopsy method for swift cancer detection.

The company’s recent $100.00K Post-IPO equity investment on March 26, 2024, underscores growing investor confidence. With ongoing clinical trials for human medicine and successful applications in veterinary care, Volition is positioned for substantial growth, aimed at saving lives worldwide.

Business keywords: early disease diagnosis, epigenetics, cancer detection, liquid biopsy, nucleosome quantification, biomarkers, veterinary medicine, human medicine, cancer screening, Nucleosomics, routine blood tests, cost-effective diagnostics, disease progression monitoring, Capture-PCR technology

Services & Products

Development of epigenetic diagnostic tests
Blood-based assays for disease detection
Capture and analysis of circulating tumor DNA
Providing diagnostic solutions for veterinary medicine

Target Customers

Clinicians Veterinarians Pharmaceutical Companies Biotech Researchers Healthcare Institutions

Funding Rounds & Investors (15)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity Undisclosed -
01 Feb 2026
Post-IPO Equity $6.00M -
01 Oct 2025
Post-IPO Equity $1.90M -
01 Dec 2024
Post-IPO Equity $7.00M -
01 Aug 2024
Post-IPO Debt $2.71M 1
Wallonie Entreprendre
01 Dec 2023
Post-IPO Equity $16.50M -
01 Jun 2023
Post-IPO Equity $7.50M -
01 Feb 2023
Post-IPO Equity $1.50M 1
Namur Invest
Namur Invest
01 Aug 2022
Post-IPO Equity $20.00M -
01 Feb 2021
Grant Undisclosed -
01 Jul 2019

View All 15 Funding Rounds

Volition Alternatives & Competitors

View All Alternatives
Volition vs
Adela, Inc.
Adela, Inc. United States

Advancing the field of epigenomics to transform how cancer is detected and monitored.

70 employees
Biotechnology, Pharmaceutical
Compare Volition vs Adela, Inc.
Volition vs
Exosome Diagnostics, a Bio-Techne brand
Exosome Diagnostics, a Bio-Techne brand United States

ExoDx Prostate is the only exosome-based, non-DRE, simple urine test to assess risk for HGPCa and gu...

Series C
103 employees
Biotechnology, Health Care
Compare Volition vs Exosome Diagnostics, a Bio-Techne brand
Volition vs
Infiniplex
Infiniplex

Empowering routine blood tests with advanced tumor biomarker screening for preemptive and affordable...

Seed
2-10 employees
Biotechnology, Health Care
View all alternatives

FAQ About Volition

Revolutionizing early disease diagnosis for a brighter tomorrow
Volition was founded in 2010.
Volition is headquartered in Henderson, United States.
Volition has a B2B, B2C and B2D business model. Its revenue comes from Product Sales, Licensing and Service Fee.
Volition has approximately 86 employees.
Volition has completed 15 funding rounds, raising a total of $69.10M. The latest funding stage is IPO.
Volition offers: Development of epigenetic diagnostic tests, Blood-based assays for disease detection, Capture and analysis of circulating tumor DNA, Providing diagnostic solutions for veterinary medicine.
Top alternatives and competitors to Volition include Adela, Inc., Exosome Diagnostics, a Bio-Techne brand, Infiniplex, VisionGate, Inc., Singlera Genomics Incorporated. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Volition and Adela, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Volition, https://bouncewatch.com/company/volition-1, updated 2 April 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout